PER 1.23% 8.0¢ percheron therapeutics limited

wow

  1. 1,395 Posts.
    lightbulb Created with Sketch. 24
    "ANP also advises that subsequent to the Company’s trading halt, a Pharmaceutical Company that has
    previously expressed an interest in ATL103 has indicated to ANP its desire to move into licensing due
    diligence. While ANP is entertaining this interest from the Pharmaceutical Company, it has not
    committed to partnering ATL1103 at this stage of the drug’s development and will continue its
    planning to progress ATL1103’s development towards a Phase II clinical trial"
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.